Figure 1

![Figure 1: Clinical outcome data from a trial of probiotic VSL#3 in patients with irritable bowel syndrome, evaluating effects on colonic permeability and abdominal pain symptoms. The safety trial assessed treatment duration and its impact on gut barrier function and microbiome composition.]()

> Source: Prapaporn Boonma et al. "Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Sympto." *Frontiers in pain research (Lausanne, Switzerland)*, 2021. PMID: [35295488](https://pubmed.ncbi.nlm.nih.gov/35295488/)

<figure>
  <img src="" alt="Clinical outcome data from a trial of probiotic VSL#3 in patients with irritable bowel syndrome, evaluating effects on colonic permeability and abdominal pain symptoms. The safety trial assessed treatment duration and its impact on gut barrier function and microbiome composition." />
  <figcaption>Figure 1. Clinical outcome data from a trial of probiotic VSL#3 in patients with irritable bowel syndrome, evaluating effects on colonic permeability and abdominal pain symptoms. The safety trial assessed treatment duration and its impact on gut barrier function and microbiome composition.<br>  Source: Prapaporn Boonma et al. "Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Sympto." <em>Frontiers in pain research (Lausanne, Switzerland)</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35295488/">35295488</a></figcaption>
</figure>